Yasir Y. Elamin

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Oct 6, 2023 | onclive.com | Yasir Y. Elamin

October 6, 2023Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

May 25, 2023 | mdpi.com | Xiuning Le |Yasir Y. Elamin |Jianjun Zhang

Open AccessEditorialby 1,†, 1,† and 1,2,*,† 1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA2Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA*Author to whom correspondence should be addressed. †These authors contributed equally to this work.